Stanford geneticist Gary Peltz uses Co-Scientist to identify drug-repurposing candidates that could lead to new treatments for chronic liver disease and fibrosis

DM provides a diverse range of content spanning technology, business, and culture, offering articles, interviews, and analysis for readers interested in staying updated with the latest trends and developments across various industries. Readers can learn about emerging technologies, industry insights, and  perspectives from experts in different fields.

DeepMind

Stanford geneticist Gary Peltz used Google DeepMind's Co-Scientist AI to identify drug repurposing candidates for liver fibrosis. Co-Scientist proposed three drugs; two of them successfully blocked fibrosis and promoted liver cell regeneration in human cell tests, while Peltz's own two picks showed no benefit. The standout candidate, cancer drug vorinostat, blocked 91% of a key damage response driving liver scarring. The findings suggest that drugs reshaping gene activity — rather than targeting a single fibrosis pathway — could form a new generation of anti-fibrotic treatments.